Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,273,814 papers from all fields of science
Search
Sign In
Create Free Account
Linagliptin
Known as:
1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-
, (R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
, Linagliptin [Chemical/Ingredient]
Expand
A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
25 relations
24 HR Linagliptin 5 MG / Metformin hydrochloride 1000 MG Extended Release Oral Tablet
Dipeptidyl Peptidase 4 Inhibitors [MoA]
In Blood
Indigo Carmine
Expand
Narrower (3)
BI 1356
Glyxambi
Tradjenta
Broader (3)
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Incretins
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
J. Rosenstock
,
V. Perkovic
,
+16 authors
D. McGuire
Journal of the American Medical Association (JAMA…
2019
Corpus ID: 53285379
Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3…
Expand
Highly Cited
2019
Highly Cited
2019
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
J. Rosenstock
,
S. Kahn
,
+12 authors
N. Marx
Journal of the American Medical Association (JAMA…
2019
Corpus ID: 202689774
Importance Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials…
Expand
Highly Cited
2016
Highly Cited
2016
DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization
F. Zhuge
,
Y. Ni
,
+5 authors
Tsuguhito Ota
Diabetes
2016
Corpus ID: 30142617
Dipeptidyl peptidase 4 (DPP-4) cleaves a large number of chemokine and peptide hormones involved in the regulation of the immune…
Expand
Highly Cited
2015
Highly Cited
2015
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
N. Marx
,
J. Rosenstock
,
+10 authors
H. Woerle
Diabetes & vascular disease research
2015
Corpus ID: 2862516
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial…
Expand
Highly Cited
2014
Highly Cited
2014
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
K. Kanasaki
,
Sen Shi
,
+7 authors
D. Koya
Diabetes
2014
Corpus ID: 7661996
Kidney fibrosis is the final common pathway of all progressive chronic kidney diseases, of which diabetic nephropathy is the…
Expand
Review
2014
Review
2014
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
R. Holman
,
H. Sourij
,
R. Califf
The Lancet
2014
Corpus ID: 5064731
Review
2014
Review
2014
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
E. Cersosimo
,
Carolina Solis-Herrera
,
M. Trautmann
,
Jaret Malloy
,
C. Triplitt
Current Diabetes Reviews
2014
Corpus ID: 6252537
Type 2 diabetes mellitus (T2DM) is characterized by a progressive failure of pancreatic β-cell function (BCF) with insulin…
Expand
Highly Cited
2013
Highly Cited
2013
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
P. Groop
,
M. Cooper
,
V. Perkovic
,
A. Emser
,
H. Woerle
,
M. von Eynatten
Diabetes Care
2013
Corpus ID: 12548351
OBJECTIVE Preclinical data suggest that linagliptin, a dipeptidyl peptidase-4 inhibitor, may lower urinary albumin excretion. The…
Expand
Highly Cited
2012
Highly Cited
2012
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
B. Gallwitz
,
J. Rosenstock
,
+5 authors
H. Woerle
The Lancet
2012
Corpus ID: 205965981
Highly Cited
2008
Highly Cited
2008
(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior…
Leo Thomas
,
M. Eckhardt
,
Elke. Langkopf
,
M. Tadayyon
,
F. Himmelsbach
,
M. Mark
Journal of Pharmacology and Experimental…
2008
Corpus ID: 16181446
BI 1356 [proposed trade name ONDERO; (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required